Navigation Links
Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
Date:5/21/2008

Seven Abstracts Accepted for Presentation at ASCO

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold an investor and analyst briefing in conjunction with the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) from 6:00 p.m. to 8:00 p.m. CT on Monday, June 2, 2008.

Participants:

-- George A. Scangos, PhD, President and Chief Executive Officer

-- Michael M. Morrissey, PhD, President of Research and Development

-- Gisela M. Schwab, MD, Executive Vice President and Chief Medical

Officer

Topics:

-- XL184 (targets: MET, VEGFR2, RET)

-- XL147 (targets: PI3K)

-- XL765 (targets: PI3K, mTOR)

-- XL647 (targets: EGFR, HER2, VEGFR2)

-- XL880* (targets: MET, VEGFR2)

-- XL281 (targets: RAF)

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archived replay of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are: 1-888- 286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode is: 42662164.

ASCO Presentations

Saturday, May 31

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"A phase 1 study of XL647, an EGFR, HER2, VEGFR2 inhibitor,

administered orally daily to patients (pts) with advanced solid

malignancies (ASM)"

Day: Saturday, May 31

Session: Developmental Therapeutics: Molecular Therapeutics

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-1 p.m. Location: W375a

Poster Number: 5 Abstract Number: 3528

Presenter: Heather A. Wakelee, MD

-- XL880* (MET, VEGFR2) -- Poster

"A phase 2 study of the dual MET/VEGFR2 inhibitor GSK1363089 (XL880)

in patients with papillary renal carcinoma (PRC)"

Day: Saturday, May 31

Session: Genitourinary Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 5G Abstract Number: 5103

Presenter: Ramiprasad Srinivasan, MD, PhD

-- XL765 (PI3K, mTOR) -- Oral Presentation

"A phase 1 dose-escalation study of the safety, pharmacokinetics

(PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765,

administered orally to patients (pts) with advanced solid tumors"

Day: Saturday, May 31

Session: PI-3 Kinase/mTOR Directed Agents

Time: 1:45-2:15 pm

Location: W375a

Abstract Number: 3510

Presenter: Kyriakos Papadopoulis, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

Sunday, June 1

-- XL184 (RET, MET, VEGFR2) -- Oral Presentation

"A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor,

in patients (pts) with advanced malignancies, including pts with

medullary thyroid cancer (MTC)"

Day: Sunday, June 1

Session: Developmental Therapeutics: Molecular Therapeutics

Time: 10-10:15 a.m.

Location: W375a

Abstract Number: 3522

Presenter: Ravi Salgia, MD, PhD

-- XL647 (EGFR, HER2, VEGFR2) -- Poster

"Activity of XL647 in clinically selected NSCLC patients (pts)

enriched for the presence of EGFR mutations: Results from phase 2"

Day: Sunday, June 1

Session: Lung Cancer -- Metastatic

Time: 2-6 p.m.

Location: S Hall A1

Poster Number: 42H Abstract Number: 8053

Presenter: Naiyer A Rizvi, MD

Monday, June 2

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"Activity and tolerance of XL647 in NSCLC patients with acquired

resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"

Day: Monday, June 2

Session: Lung Cancer -- Metastatic

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-12:15 p.m. Location: W375d

Poster Number: 9 Abstract Number: 8028

Presenter: Vincent A. Miller, MD

-- XL880* (MET, VEGFR2) -- Poster

"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2

inhibitor, in MET amplified poorly differentiated gastric cancer

(PDGC): Interim results of a multicenter phase 2 study"

Day: Monday, June 2

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 33D Abstract Number: 4572

Presenter: Minaxi P. Jhawer, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ALBANY, New York , April 29, 2016 ... market report published by Transparency Market Research "Separation ... Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... market was valued at US$ 10,665.5 Mn in ... CAGR of 6.8% from 2015 to 2023 to ...
(Date:4/29/2016)... San Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Cell Foundation (NSCF) to support the development of a patient-specific stem cell therapy for ... Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps Research Institute in ...
(Date:4/29/2016)... Elekta is pleased to announce ... industry-leading treatment planning software, is available for clinical release. ... version 5.11 provides significant performance speed enhancements over ... to four times faster than in previous versions of ... standard Monte Carlo algorithm, users ...
(Date:4/28/2016)... 2016 Q BioMed Inc. ... CEO  was featured in an article he wrote ... Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life science ... to Big Pharmas. Their content is designed to ...
Breaking Biology Technology:
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI Strategic ... of Innovation, Research & Development, Leadership in Education, and, ... is the 9 th year of the FLEXI ... companies and individuals from past years . Judging ... a pre-described set of criteria, by a panel of ...
(Date:3/2/2016)... 2, 2016 ... of the  "Global Biometrics Market in Hospitality ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics market ... a CAGR of around 27%   ... announced the addition of the  "Global Biometrics ...
Breaking Biology News(10 mins):